Technical Data
S9500-20A
Synuclein, alpha (SNCA, 127750, P37840, MGC110988, NACP, PARK1, PARK4, non-A beta Component of AD Amyloid, NACP, Parkinson Disease Familial 1, PD1)
Description:
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by progressive loss of memory and cognition in the elderly. An early step involves proteolytic cleavage of amyloid precursor protein (APP, chromosome 21) releasing short 40, 42 & 43aa peptides (beta amyloid1-40, 1-42, and 1-43). Polymerization of b-amyloid (Ab) and subsequent neuronal deposit (amyloid) leads to the degeneration of neurons involved in memory and cognition. Ab deposits have also been found to contain 2 additional proteins termed a-synuclein and b-synuclein. The 140aa a-synuclein is identical with non-Ab component (NACP) of AD. The 134aa b-synuclein is homologous to 14kD bovine phosphoneuroprotein 14. Mutations in a-synuclein gene causing a replacement of alanine with a threonine has the potential to cause the protein to misfold.

Applications:
Suitable for use in Western Blot, ELISA, and Immunoprecipitation. Other applications not tested.

Recommended Dilution:
Western Blot: 1:1,000-1:5,000
ELISA: 1:10,000-1:100,000; 50-100ng of control peptide/well
Immunoprecipitation: 5-10ul
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabSerum
SizeStorageShippingSourceHost
100ul-20°CBlue IceHumanRabbit
Concentration:
As reported
Immunogen:
Synthetic peptide corresponding to 15aa located near the C-terminus of human synuclein-alpha (KLH).
Purity:
Serum
Form
Supplied as a lyophilized powder from PBS, 0.05% sodium azide.
Specificity:
Recognizes human synuclein-alpha.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Jakes et al (1994) FEBS Lett. 345, 27-32. 2. Ueda K et al (1993) PNAS 90, 11282-11286. 3. Maroteaux L. et al (1988) J Neurosci. 8, 2804-2815. 4. Maroteaux L et al (1991) Mol. Brain Res. 11, 335-343.